Journals / Turkish Journal of Obstetrics and Gynecology / 2016 / Cilt: 13 - Sayı: 1

Farklı polikistik over sendromunun fenotiplerinin in vitro fertilizasyon özellikleri ve sonuçlarının karşılaştırılması

Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome

Pages
1–6
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the end point is similar in terms of biochemical, clinical, and ongoing pregnancy rates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate whether polycystic ovary syndrome (PCOS) phenotype without polycystic ovaries (PCO) differs in terms of in vitro fertilization (IVF) outcomes compared with classic phenotypes.Materials and Methods: This retrospective controlled study included 262 patients who underwent IVF treatment with an indication of unexplained or tubal factor infertility (control group), ovulatory patients with PCO morphology (group 1), PCOS phenotype with oligoanovulation and hyperandrogenemia (group 2), PCOS phenotype with PCO morphology and oligoanovulation (group 3).
📊
Key Findings & Data:Basal follicle-stimulating hormone level (beta coefficient=0.207, p=0.003), group (beta coefficient=-0.305, p<0.001) and age (beta coefficient=0.311, p<0.001) were significantly associated with the total gonadotropin dose.
💡
Conclusion & Impact:However, the end point is similar in terms of biochemical, clinical, and ongoing pregnancy rates.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to investigate whether polycystic ovary syndrome (PCOS) phenotype without polycystic ovaries (PCO) differs in terms of in vitro fertilization (IVF) outcomes compared with classic phenotypes.Materials and Methods: This retrospective controlled study included 262 patients who underwent IVF treatment with an indication of unexplained or tubal factor infertility (control group), ovulatory patients with PCO morphology (group 1), PCOS phenotype with oligoanovulation and hyperandrogenemia (group 2), PCOS phenotype with PCO morphology and oligoanovulation (group 3). Outcomes and baseline characteristics of IVF-embryo transfer treatments were compared among all groups. Results: PCOS phenotype without PCO morphology had similar IVF stimulation characteristics compared with classic phenotypes; however, a higher total gonadotropin dose was needed to achieve similar results compared with patients with PCO morphology with or without PCOS. Basal follicle-stimulating hormone level (beta coefficient=0.207, p=0.003), group (beta coefficient=-0.305, p<0.001) and age (beta coefficient=0.311, p<0.001) were significantly associated with the total gonadotropin dose. The number of good quality embryo on transfer day was significantly lower in patients with isolated PCO morphology and PCO morphology with oligoanovulation than in those with PCOS phenotype without PCO morphology.Conclusion: PCO morphology provides easier stimulation, whereas hyperandrogenemia provides better results as good quality embryos. However, the end point is similar in terms of biochemical, clinical, and ongoing pregnancy rates.

Özet

Amaç: Bu çalışmada polikistik over sendromunun (PKOS) farklı fenotiplerinin in vitro fertilizasyon (İVF) sonuçlarının karşılaştırılması amaçlandı.Gereç ve Yöntemler: Bu retrospektif çalışmaya IVF tedavisi uygulanmış açıklanamayan veya tubal faktör infertilitesi olan hastalar (kontrol grup), polikistik over (PKO) morfolojisi olan ovulatuar hastalar (grup 1), oligo-anovulasyonu ve hiperandrojenemisi olan PKOS'lu hastalar (grup 2), PKO morfolojisi ve oligo-anovulasyonu olan hastalar (grup 3) olmak üzere toplam 262 hasta dahil edildi. Gruplar uygulanan İVF-embriyo transferi tedavisinin özellikleri ve sonuçları açısından karşılaştırıldı.Bulgular: PKO morfolojisi olmayan PKOS'lu olgular; klasik PKOS fenotipi olan olgularla karşılaştırıldığında benzer over stimulasyon özellikleri göstermektedir ancak PKO morfolojisi olan olgulara göre daha yüksek gonadotropin dozu gerekmektedir. Bazal folikül uyarıcı hormon düzeyi (beta kat sayısı=0,207, p=0,003), grup (beta kat sayısı=-0,305, p<0,001) ve yaş (beta kat sayısı=0,311, p<0,001) toplam gonadotropin dozuyla istatistiksel olarak anlamlı derecede ilişkili bulundu. İzole PKO morfolojisi olan olguların ve oligo-anovulasyonu olup PKO morfolojisi olan olguların transfer günü iyi kalite embriyo sayısı, PKO morfolojisi olmayan PKOS'lu olgulara göre istatistiksel olarak anlamlı düzeyde daha düşük tespit edildi.Sonuç: PKO morfolojisinin varlığının over stimulasyonunu kolaylaştırdığı, hiperandrojeneminin de embriyo kalitesi üzerine olumlu etkilerinin olduğu saptandı. Ancak gruplar arasında; biyokimyasal gebelik, klinik gebelik ve devam eden gebelik oranları açısından fark tespit edilmedi.

🔖

Cite This Article

SELÇUK, S., ÖZKAYA, E., ESER, A., KUYUCU, M., KUTLU, H. T., DEVRANOĞLU, B., SOFUOĞLU, K., DAYICIOĞLU, V. E. (2016). Farklı polikistik over sendromunun fenotiplerinin in vitro fertilizasyon özellikleri ve sonuçlarının karşılaştırılması. Turkish Journal of Obstetrics and Gynecology, Cilt: 13 - Sayı: 1, 1–6. https://ajindex.com/articles/376428

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston, Blackwell Scientific; 1992.p.377-84.
  2. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 2006;91:3922-7.
  3. Azziz R, Carmina E, Dewailly D, DiamantiKandarakis E, Escobar- Morreale HF, Futterweit W, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237-45. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  4. Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: Impact on oocyte maturation and embryo developmental competence. Hum Reprod Update 2011;17:17-33. Carmine E. Ovarian and adrenal hyperandrogenism. Ann NY Acad Sci 2006;1092:130-7.
  5. Carmina E, Lobo RA. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest 2007;30:111-6.
  6. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2005;62:644-9.
  7. Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: Rationale and results. Curr Opin Obstet Gynecol 2009;21:306-8.
  8. Kim YJ, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM, et al. A comparative study on the outcomes of in vitro fertilization between women with polycystic ovary syndrome and those with sonographic polycystic ovary-only in GnRH antagonist cycles. Arch Gynecol Obstet 2010;282:199-205. IVF: in vitro fertilization Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505-14.
  9. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-30.
  10. Van Royen E, Mangelschots K, De Neubourg D, Valkenburg M, Van de Meerssche M, Ryckaert G, et al. Characterization of a top quality embryo, a step towards single-embryo transfer. Hum Reprod 1999;14:2345-9. Alpha Scientists in Reproductive Medicine and ESHRE